ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 45 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,604 | +69.0% | 16,161 | -56.5% | 0.00% | – |
| Q2 2023 | $12,192 | -21.3% | 37,110 | -1.3% | 0.00% | – |
| Q1 2023 | $15,486 | -3.2% | 37,609 | +19.9% | 0.00% | – |
| Q4 2022 | $16,000 | -33.3% | 31,359 | +0.6% | 0.00% | – |
| Q3 2022 | $24,000 | -36.8% | 31,159 | -4.0% | 0.00% | – |
| Q2 2022 | $38,000 | -72.9% | 32,459 | +99.2% | 0.00% | – |
| Q1 2022 | $140,000 | +288.9% | 16,294 | +28.7% | 0.00% | – |
| Q4 2021 | $36,000 | -21.7% | 12,662 | +16.1% | 0.00% | – |
| Q3 2021 | $46,000 | -22.0% | 10,902 | -4.0% | 0.00% | – |
| Q2 2021 | $59,000 | +7.3% | 11,352 | -4.8% | 0.00% | – |
| Q1 2021 | $55,000 | +52.8% | 11,925 | +5.2% | 0.00% | – |
| Q4 2020 | $36,000 | -47.8% | 11,335 | -46.4% | 0.00% | – |
| Q3 2020 | $69,000 | -36.1% | 21,135 | -34.3% | 0.00% | – |
| Q2 2020 | $108,000 | -8.5% | 32,155 | +4.4% | 0.00% | – |
| Q1 2020 | $118,000 | – | 30,786 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ETF MANAGERS GROUP, LLC | 2,679,457 | $20,257,000 | 0.73% |
| Portolan Capital Management | 777,293 | $5,876,000 | 0.66% |
| CAMPBELL CAPITAL MANAGEMENT INC | 110,451 | $835,000 | 0.62% |
| ZEKE CAPITAL ADVISORS, LLC | 402,212 | $3,041,000 | 0.27% |
| Leap Investments LP | 46,084 | $348,000 | 0.17% |
| Bernardo Wealth Planning LLC | 26,419 | $199,000 | 0.14% |
| Claraphi Advisory Network, LLC | 14,744 | $111,000 | 0.07% |
| Sterling Investment Advisors, Ltd. | 11,000 | $83,000 | 0.04% |
| A.R.T. Advisors, LLC | 81,372 | $615,000 | 0.03% |
| Mirae Asset Global Investments Co., Ltd. | 544,408 | $4,116,000 | 0.03% |